The end of a dogma: The safety of doxycycline use in young children for malaria treatment

Malaria Journal

Volumn 16, Issue 1, 2017, Pages

  Gaillard, Tiphaine ^a   Briolant, Sébastien ^b,c   Madamet, Marylin ^b,c,d   Pradines, Bruno ^b,c,d  

^a HIA Desgenettes   (France)

^b LAVERAN MILITARY TEACHING HOSPITAL   (France)

^c AIX MARSEILLE UNIVERSITÉ   (France)

^d Centre National de Reference du Paludisme   (France)

Author keywords

Anti malarial drug; Antibiotics; Children; Doxycycline; Malaria; Plasmodium falciparum; Prophylaxis; Resistance; Treatment

Indexed keywords

AMODIAQUINE; AMODIAQUINE PLUS ARTESUNATE; ARTESUNATE; CHLORTETRACYCLINE; DIHYDROARTEMISININ PLUS PIPERAQUINE; DOXYCYCLINE; OXYTETRACYCLINE; PYRIMETHAMINE PLUS SULFADOXINE; TETRACYCLINE; ANTIMALARIAL AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; CHILD; CHILDHOOD DISEASE; CYSTIC FIBROSIS; DRUG CONTRAINDICATION; DRUG SAFETY; ENAMEL HYPOPLASIA; HUMAN; MALARIA; MALARIA CONTROL; NONHUMAN; PNEUMONIA; Q FEVER; RANDOMIZED CONTROLLED TRIAL (TOPIC); ROCKY MOUNTAIN SPOTTED FEVER; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TOOTH DISCOLORATION; ADVERSE DRUG REACTION; ADVERSE EFFECTS; CHEMICALLY INDUCED; CHEMOPROPHYLAXIS; INFANT; NEWBORN; PRESCHOOL CHILD; PROCEDURES;

ANTIMALARIALS; CHEMOPREVENTION; CHILD; CHILD, PRESCHOOL; DENTAL ENAMEL HYPOPLASIA; DOXYCYCLINE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; INFANT; INFANT, NEWBORN; MALARIA;

EID: 85018523831     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/s12936-017-1797-9     Document Type: Article

References (63)

1. WHO. World Malaria Report 2016. Geneva: World Health Organization; 2016.
2. Mita T, Venkatesan M, Ohashi J, Culleton R, Takahashi N, Tsukahara T, et al. Limited geographical origin and global spread of sulfadoxine-resistant dhps alleles in Plasmodium falciparum populations. J Infect Dis. 2011;204:1980-8.
3. Wootton JC, Feng X, Ferdig MT, Cooper RA, Mu J, Baruch DI, et al. Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum. Nature. 2002;418:320-3.
4. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455-67.
5. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2015;371:411-23.
6. Leang R, Taylor WR, Bouth DM, Song L, Tarning J, Char MC, et al. Evidence of Plasmodium falciparum malaria multidrug resistance to artemisinin and piperaquine in Western Cambodia: Dihydroartemisinin-Piperaquine open-label multicenter clinical assessment. Antimicrob Agents Chemother. 2015;59:4719-26.
7. Spring MD, Lin JT, Manning JE, Vanachayangkul P, Somethy S, Bun R, et al. Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet Infect Dis. 2015;15:683-91.
8. Amaratunga C, Lim P, Suon S, Sreng S, Mao S, Sopha C, et al. Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study. Lancet Infect Dis. 2016;16:357-65.
9. Gaillard T, Dormoi J, Madamet M, Pradines B. Macrolides and associated antibiotics based on similar mechanism of action like lincosamides in malaria. Malar J. 2016;15:85.
10. Gaillard T, Madamet M, Foguim Tsombeng F, Dormoi J, Pradines B. Antibiotics in malaria therapy: which antibiotics except tetracyclines and macrolides may be used against malaria? Malar J. 2016;15:556.
11. Gaillard T, Madamet M, Pradines B. Tetracyclines in malaria. Malar J. 2015;14:445.
12. CDC. Health information for international travel. Yellow book 2016. Atlanta: Centers for Diseases Control and Prevention; 2016.
13. Haut Conseil de la Santé Publique. Recommandations sanitaires pour les voyageurs 2016. Bulletin Epidémiologique Hebdomadaire, hors série, 2016.
14. Société de Pathologie Infectieuse de Langue Française. Recommendations for clinical practice Management and prevention of imported Plasmodium falciparum malaria (Revision 2007 of the 1999 Consensus conference). Med Mal Infect. 2008;38:54-67.
15. Lalloo DG, Shingadia D, Bell DJ, Beeching NJ, Whitty CJ, Chiodini PL. PHE Advisory Committee on Malaria Prevention in UK Travellers. UK malaria treatment guidelines 2016. J Infect. 2016;2:635-49.
16. Van Hong N, Amambua-Ngwa A, Tuan NQ, Cuong do D, Giang NT, Van Dung N, et al. Severe malaria not responsive to artemisinin derivatives in man returning from Angola to Vietnam. Emerg Infect Dis. 2014;20:1199-202.
17. Diawara S, Madamet M, Kounta MB, Lo G, Wade KA, Nakoulima A, et al. Confirmation of Plasmodium falciparum in vitro resistance to monodesethylamodiaquine and chloroquine in Dakar, Senegal, in 2015. Malar J. 2017;16:118.
18. Gupta H, Dhunputh P, Bhatt AN, Satyamoorthy K, Umakanth S. Cerebral malaria in a man with Plasmodium vivax mono-infection: a case report. Trop Doct. 2016;46:241-5.
19. Amireh S, Shaaban H, Guron G. Severe Plasmodium vivax cerebral malaria complicated by hemophagocytic lymphohistiocytosis treated with artesunate and doxycycline. Hematol Oncol Stem Cell Ther. 2016;3876(16):30035-8.
20. Shwachman H, Fekete E, Kulczycki LL, Foley GE. The effect of long-term antibiotic therapy in patients with cystic fibrosis of the pancreas. Antibiot Annu. 1958;6:692-9.
21. Swallow JN, De Haller J, Young WF. Side-effects to antibiotics in cystic fibrosis: dental changes in relation to antibiotic administration. Arch Dis Child. 1967;42:311-8.
22. Zegarelli EV, Denning CR, Kutscher AH, Fahn B, Kirschner G, Slaughter TW. Discoloration of teeth in patients with cystic fibrosis of the pancreas: role of tetracycline therapy. Clin Pediatr (Phila). 1963;2:329-31.
23. Wallman IS, Hilton HB. Teeth pigmented by tetracycline. Lancet. 1962;1:827-9.
24. Conchie JM, Munroe JD, Anderson DO. The incidence of staining of permanent teeth by the tetracyclines. Can Med Assoc J. 1970;103:351-6.
25. Kowalewska B, Szotowa W, Winiarska-Majczyno M. Tetracyclines and the teeth. Lancet. 1966;2:387.
26. Rebich T, Kumar J, Brustman B. The St. Regis environmental health issue: assessment of dental defects. J Am Dental Assoc. 1983;106:630-3.
27. Ibsen KH, Urist MR, Sognnaes RF. Differences among tetracyclines with respect to the staining of teeth. J Pediatr. 1965;67:459-62.
28. Forti G, Beniucori C. Doxycycline and the teeth. Lancet. 1969;1:782.
29. Tredwin CJ, Scully C, Bagan-Sebastian JV. Drug-induced disorders of teeth. J Dent Res. 2005;84:596-602.
30. Caswell AH, Hutchison JD. Selectivity of cation chelation to tetracyclines: evidence for special conformation of calcium chelate. Biochem Biophys Res Commun. 1971;43:625-30.
31. Lambrou DB, Tahos BS, Lambrou KD. In vitro studies of the phenomenon of tetracycline incorporation into enamel. J Dent Res. 1977;56:1527-32.
32. Lochary ME, Lockhart PB, Williams WT. Doxycycline and staining of permanent teeth. Pediatr Infect Dis J. 1998;17:429-31.
33. Volovitz B, Shkap R, Amir J, Calderon S, Varsano I, Nussinovitch M. Absence of tooth staining with doxycycline treatment in young children. Clin Pediatr. 2007;46:121-6.
34. Todd SR, Dahlgren S, Traeger MS, Beltran-Aguilar ED, Marianos DW, Hamilton C, et al. No visible dental staining in children treated with doxycycline for suspected Rocky Mountain spotted fever. J Pediatr. 2015;166:1246-51.
35. Baxter BT, Pearce WH, Waltke EA, et al. Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: report of a prospective (Phase II) multicenter study. J Vasc Surg. 2002;36:1-12.
36. Smith K, Leyden JJ. Safety od doxycycline and minocycline: a systematic review. Clin Ther. 2005;27:1329-42.
37. Cross R, Ling C, Day NP, McGready R, Paris DH. Revisiting doxycycline in pregnancy and early childhood-time to rebuild its reputation? Expert Opin Drug Saf. 2016;15:367-82.
38. Long SS. Good news about doxycycline and dental staining. J Pediatr. 2015;166:1101-4.
39. Cale DF, McCarthy MW. Treatment of Rocky Mountain spotted fever in children. Ann Pharmacother. 1997;31:492-4.
40. Anonymes. Addentum: Doxycycline for young children. Med Lett Drug Ther. 2016;58:82.
41. CDC. Diagnosis and management of Q fever-United States. Recommendations from CDC and the Q fever working group. MMWR Recomm Rep. 2013;2013(62):1-29.
42. Biggs HM, Behravesh CB, Bradley KK, Dahlgren FS, Drexler NA, Dumler JS, et al. Diagnosis and Management of Tickborne Rickettsial Diseases: Rocky Mountain Spotted Fever and Other Spotted Fever Group Rickettsioses, Ehrlichioses, and Anaplasmosis - United States. MMWR Recomm Rep. 2016;65:1-44.
43. WHO. Guidelines for the treatment of malaria. 3rd edition. Geneva: World Health Organization; 2015.
44. Meremikwu MM, Donegan S, Sinclair D, Esu E, Oringanje C. Intermittent preventive treatment for malaria in children living in areas with seasonal transmission. Cochrane Database System Rev. 2012;15:CD003756.
45. Matangila JR, Mitashi P, Inocêncio da Luz RA, Lutumba PT, Van Geertruyden JP. Efficacy and safety of intermittent preventive treatment for malaria in schoolchildren: a systematic review. Malar J. 2015;14:450.
46. Nankabirwa JI, Wandera B, Amuge P, Kiwanuka N, Dorsey G, Rosenthal PJ, et al. Impact of intermittent preventive treatment with dihydroartemisinin-piperaquine on malaria in Ugandan schoolchildren: a randomized, placebo-controlled trial. Clin Infect Dis. 2014;58:1404-12.
47. Clarke SE, Brooker S, Njagi JK, Njau E, Estambale B, Muchiri E, et al. Malaria morbidity among school children living in two areas of contrasting transmission in western Kenya. Am J Trop Med Hyg. 2004;71:732-8.
48. Clarke SE, Jukes MC, Njagi JK, Khasakhala L, Cundill B, Otido J, et al. Effect of intermittent preventive treatment of malaria on health and education in schoolchildren: a cluster-randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:127-38.
49. Dicko A, Sagara I, Sissoko MS, Guindo O, Diallo AI, Kone M, et al. Impact of intermittent preventive treatment with sulphadoxine-pyrimethamine targeting the transmission season on the incidence of clinical malaria in children in Mali. Malar J. 2008;7:123.
50. Barger B, Maiga H, Traore OB, Tekete M, Tembine I, Dara A, et al. Intermittent preventive treatment using artemisinin-based combination therapy reduces malaria morbidity among school-aged children in Mali. Trop Med Int Health. 2009;14:784-91.
51. Nankabirwa J, Cundill B, Clarke S, Kabatereine N, Rosenthal PJ, Dorsey G, et al. Efficacy, safety, and tolerability of three regimens for prevention of malaria: a randomized, placebo-controlled trial in Ugandan schoolchildren. PLoS ONE. 2010;5:e13438.
52. Tine RC, Faye B, Ndour CT, Ndiaye JL, Ndiaye M, Bassene C, et al. Impact of combining intermittent preventive treatment with home management of malaria in children less than 10 years in a rural area of Senegal: a cluster randomized trial. Malar J. 2011;10:358.
53. Dahl EL, Shock JL, Shenai BR, Gut J, DeRisi JL, Rosenthal PJ. Tetracyclines specifically target the apicoplast of the malaria parasite Plasmodium falciparum. Antimicrob Agents Chemother. 2006;50:3124-31.
54. Briolant S, Almeras L, Belghazi M, Boucomont-Chapeaublanc E, Wurtz N, Fontaine JC, et al. Plasmodium falciparum proteome changes in response to doxycycline treatment. Malar J. 2010;9:141.
55. Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev. 2001;65:232-60.
56. Angelakis E, Merhej V, Raoult D. Related actions of probiotics and antibiotics on gut microbiota and weight modification. Lancet Infect Dis. 2013;13:889-99.
57. Bäumler AJ, Sperandio V. Interactions between the microbiota and pathogenic bacteria in the gut. Nature. 2016;535:85-93.
58. Angelakis E, Million M, Kankoe S, Lagier JC, Armougom F, Giorgi R, et al. Abnormal weight gain and gut microbiota modifications are side effects of long-term doxycycline and hydroxychloroquine treatment. Antimicrob Agents Chemother. 2014;58:3342-7.
59. Taylor DN, Pitarangsi C, Echeverria P, Diniega BM. Campylobacter enteritis during doxycycline prophylaxis for malaria in Thailand. Lancet. 1988;2:578-9.
60. Arthur JD, Echeverria P, Shanks GD, Karwacki J, Bodhidatta L, Brown JE. A comparative study of gastrointestinal infections in United States soldiers receiving doxycycline or mefloquine for malaria prophylaxis. Am J Trop Med Hyg. 1990;43:608-13.
61. Vento TJ, Cole DW, Mende K, Calvano TP, Rini EA, Tully C, et al. Multidrug-resistant gram-negative bacteria colonization of healthy US military personnel in the US and Afghanistan. BMC Infect Dis. 2013;13:68.
62. Vento TJ, Cole DW, Mende K, Calvano TP, Rini EA, Tully C, et al. Staphylococcus aureus colonization of healthy military service members in the United States and Afghanistan. BMC Infect Dis. 2013;13:325.
63. Lesens O, Haus-Cheymol R, Dubrous P, Verret C, Spiegel A, Bonnet R, et al. Methicillin-susceptible, doxycycline-resistant Staphylococcus aureus, Côte d'Ivoire. Emerg Infect Dis. 2007;13:488-90.